These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. Witjes WP; Witjes JA; Oosterhof GO; Debruyne MJ Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):10-6. PubMed ID: 8727805 [TBL] [Abstract][Full Text] [Related]
6. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor. Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252 [TBL] [Abstract][Full Text] [Related]
7. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. Shahin O; Thalmann GN; Rentsch C; Mazzucchelli L; Studer UE J Urol; 2003 Jan; 169(1):96-100; discussion 100. PubMed ID: 12478112 [TBL] [Abstract][Full Text] [Related]
8. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315 [TBL] [Abstract][Full Text] [Related]
9. Do bacteriostatic urethral lubricants affect the clinical efficacy of intravesical bacillus Calmette-Guérin therapy? Loertzer H; Brake M; Horsch R; Keller H Urology; 2001 May; 57(5):900-5. PubMed ID: 11337290 [TBL] [Abstract][Full Text] [Related]
10. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer. Demkow T; Alter A; Wiechno P Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238 [TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Sylvester RJ; Brausi MA; Kirkels WJ; Hoeltl W; Calais Da Silva F; Powell PH; Prescott S; Kirkali Z; van de Beek C; Gorlia T; de Reijke TM; Eur Urol; 2010 May; 57(5):766-73. PubMed ID: 20034729 [TBL] [Abstract][Full Text] [Related]
13. Intravesical bacillus Calmette-Guérin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder. Baniel J; Grauss D; Engelstein D; Sella A Urology; 1998 Nov; 52(5):785-9. PubMed ID: 9801099 [TBL] [Abstract][Full Text] [Related]
14. Long-term maintenance bacille Calmette-Guérin therapy in high-grade superficial bladder cancer. Iori F; Di Seri M; De Nunzio C; Leonardo C; Franco G; Spalletta B; Laurenti C Urology; 2002 Mar; 59(3):414-8. PubMed ID: 11880083 [TBL] [Abstract][Full Text] [Related]
15. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer. Ajili F; Darouiche A; Chebil M; Boubaker S Ultrastruct Pathol; 2013 Aug; 37(4):278-83. PubMed ID: 23789613 [TBL] [Abstract][Full Text] [Related]
16. Low-dose BCG instillations in the treatment of stage T1 grade 3 bladder tumours: recurrence, progression and success. Lebret T; Gaudez F; Hervé JM; Barré P; Lugagne PM; Botto H Eur Urol; 1998; 34(1):67-72. PubMed ID: 9676417 [TBL] [Abstract][Full Text] [Related]
17. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study. Duchek M; Johansson R; Jahnson S; Mestad O; Hellström P; Hellsten S; Malmström PU; Eur Urol; 2010 Jan; 57(1):25-31. PubMed ID: 19819617 [TBL] [Abstract][Full Text] [Related]
18. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer. Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510 [TBL] [Abstract][Full Text] [Related]
19. The role of tumor-free status in repeat resection before intravesical bacillus Calmette-Guerin for high grade Ta, T1 and CIS bladder cancer. Guevara A; Salomon L; Allory Y; Ploussard G; de la Taille A; Paul A; Yiou R; Hoznek A; Dahan M; Abbou CC; Vordos D J Urol; 2010 Jun; 183(6):2161-4. PubMed ID: 20399454 [TBL] [Abstract][Full Text] [Related]
20. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer. Lerner SP; Tangen CM; Sucharew H; Wood D; Crawford ED J Urol; 2007 May; 177(5):1727-31. PubMed ID: 17437798 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]